vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Crane NXT, Co. (CXT). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $476.9M, roughly 1.0× Crane NXT, Co.). Crane NXT, Co. runs the higher net margin — 10.0% vs -10.1%, a 20.1% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 19.5%). Over the past eight quarters, Crane NXT, Co.'s revenue compounded faster (23.3% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Crane Co. is an American industrial products company based in Stamford, Connecticut. Founded by Richard Teller Crane in 1855, it became one of the leading manufacturers of bathroom fixtures in the United States, until 1990, when that division was sold off. In 1960 it began the process of becoming a holding company with a diverse portfolio. Its business segments are Aerospace & Electronics, Engineered Materials, Fluid Handling, and Controls. Industries served by these segments include chemical...

CLOV vs CXT — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.0× larger
CLOV
$487.7M
$476.9M
CXT
Growing faster (revenue YoY)
CLOV
CLOV
+25.2% gap
CLOV
44.7%
19.5%
CXT
Higher net margin
CXT
CXT
20.1% more per $
CXT
10.0%
-10.1%
CLOV
Faster 2-yr revenue CAGR
CXT
CXT
Annualised
CXT
23.3%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
CXT
CXT
Revenue
$487.7M
$476.9M
Net Profit
$-49.3M
$47.5M
Gross Margin
42.4%
Operating Margin
-10.1%
16.7%
Net Margin
-10.1%
10.0%
Revenue YoY
44.7%
19.5%
Net Profit YoY
-123.2%
EPS (diluted)
$0.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
CXT
CXT
Q4 25
$487.7M
$476.9M
Q3 25
$496.6M
$445.1M
Q2 25
$477.6M
$404.4M
Q1 25
$462.3M
$330.3M
Q4 24
$337.0M
$399.1M
Q3 24
$331.0M
$403.5M
Q2 24
$356.3M
$370.6M
Q1 24
$346.9M
$313.6M
Net Profit
CLOV
CLOV
CXT
CXT
Q4 25
$-49.3M
$47.5M
Q3 25
$-24.4M
$50.5M
Q2 25
$-10.6M
$24.9M
Q1 25
$-1.3M
$21.7M
Q4 24
$-22.1M
Q3 24
$-9.2M
$47.1M
Q2 24
$7.4M
$41.6M
Q1 24
$-19.2M
$37.8M
Gross Margin
CLOV
CLOV
CXT
CXT
Q4 25
42.4%
Q3 25
43.3%
Q2 25
41.7%
Q1 25
42.4%
Q4 24
45.2%
Q3 24
24.5%
42.5%
Q2 24
30.3%
43.4%
Q1 24
23.6%
48.6%
Operating Margin
CLOV
CLOV
CXT
CXT
Q4 25
-10.1%
16.7%
Q3 25
-4.9%
18.4%
Q2 25
-2.2%
11.8%
Q1 25
-0.3%
11.3%
Q4 24
-6.4%
17.7%
Q3 24
-2.7%
18.6%
Q2 24
2.0%
18.2%
Q1 24
-6.5%
17.7%
Net Margin
CLOV
CLOV
CXT
CXT
Q4 25
-10.1%
10.0%
Q3 25
-4.9%
11.3%
Q2 25
-2.2%
6.2%
Q1 25
-0.3%
6.6%
Q4 24
-6.6%
Q3 24
-2.8%
11.7%
Q2 24
2.1%
11.2%
Q1 24
-5.5%
12.1%
EPS (diluted)
CLOV
CLOV
CXT
CXT
Q4 25
$0.82
Q3 25
$0.87
Q2 25
$0.43
Q1 25
$0.38
Q4 24
$1.00
Q3 24
$0.81
Q2 24
$0.72
Q1 24
$0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
CXT
CXT
Cash + ST InvestmentsLiquidity on hand
$78.3M
$233.8M
Total DebtLower is stronger
$1.0B
Stockholders' EquityBook value
$308.7M
$1.3B
Total Assets
$541.0M
$3.1B
Debt / EquityLower = less leverage
0.80×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
CXT
CXT
Q4 25
$78.3M
$233.8M
Q3 25
$182.4M
Q2 25
$152.5M
Q1 25
$173.8M
Q4 24
$194.5M
$165.8M
Q3 24
$288.0M
$165.1M
Q2 24
$254.8M
$175.5M
Q1 24
$208.3M
$220.6M
Total Debt
CLOV
CLOV
CXT
CXT
Q4 25
$1.0B
Q3 25
$834.3M
Q2 25
$861.8M
Q1 25
$541.1M
Q4 24
$540.6M
Q3 24
$638.2M
Q2 24
$638.9M
Q1 24
$639.6M
Stockholders' Equity
CLOV
CLOV
CXT
CXT
Q4 25
$308.7M
$1.3B
Q3 25
$340.9M
$1.2B
Q2 25
$344.2M
$1.2B
Q1 25
$336.1M
$1.1B
Q4 24
$341.1M
$1.1B
Q3 24
$342.2M
$1.1B
Q2 24
$324.9M
$989.8M
Q1 24
$292.5M
$964.1M
Total Assets
CLOV
CLOV
CXT
CXT
Q4 25
$541.0M
$3.1B
Q3 25
$559.7M
$2.9B
Q2 25
$575.0M
$2.9B
Q1 25
$583.7M
$2.4B
Q4 24
$580.7M
$2.4B
Q3 24
$653.0M
$2.4B
Q2 24
$674.2M
$2.4B
Q1 24
$671.8M
$2.1B
Debt / Equity
CLOV
CLOV
CXT
CXT
Q4 25
0.80×
Q3 25
0.69×
Q2 25
0.73×
Q1 25
0.49×
Q4 24
0.51×
Q3 24
0.60×
Q2 24
0.65×
Q1 24
0.66×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
CXT
CXT
Operating Cash FlowLast quarter
$-66.9M
$105.8M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
2.23×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
CXT
CXT
Q4 25
$-66.9M
$105.8M
Q3 25
$12.1M
$92.0M
Q2 25
$5.4M
$62.8M
Q1 25
$-16.3M
$-19.1M
Q4 24
$34.8M
$81.1M
Q3 24
$50.0M
$66.7M
Q2 24
$44.8M
$56.8M
Q1 24
$25.9M
$9.5M
Free Cash Flow
CLOV
CLOV
CXT
CXT
Q4 25
$-69.0M
Q3 25
$11.4M
$78.7M
Q2 25
$4.8M
$55.8M
Q1 25
$-16.5M
$-32.2M
Q4 24
$33.3M
Q3 24
$49.6M
$53.5M
Q2 24
$44.4M
$47.9M
Q1 24
$25.5M
$-3.0M
FCF Margin
CLOV
CLOV
CXT
CXT
Q4 25
-14.1%
Q3 25
2.3%
17.7%
Q2 25
1.0%
13.8%
Q1 25
-3.6%
-9.7%
Q4 24
9.9%
Q3 24
15.0%
13.3%
Q2 24
12.5%
12.9%
Q1 24
7.3%
-1.0%
Capex Intensity
CLOV
CLOV
CXT
CXT
Q4 25
0.4%
Q3 25
0.1%
3.0%
Q2 25
0.1%
1.7%
Q1 25
0.0%
4.0%
Q4 24
0.5%
Q3 24
0.1%
3.3%
Q2 24
0.1%
2.4%
Q1 24
0.1%
4.0%
Cash Conversion
CLOV
CLOV
CXT
CXT
Q4 25
2.23×
Q3 25
1.82×
Q2 25
2.52×
Q1 25
-0.88×
Q4 24
Q3 24
1.42×
Q2 24
6.04×
1.37×
Q1 24
0.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

CXT
CXT

Other$260.9M55%
Products$181.1M38%
Services$34.9M7%

Related Comparisons